Sexual Health
Sexual-health treatment pathways depend on clinician review, contraindication screening, and state availability.
Clinician-guided treatment pathways
Options in this category require screening for contraindications, medication interactions, and indication-specific fit. Compounded products are not FDA-approved and are not presented as interchangeable with generic or brand drugs.
Injectable
PT-141 (Bremelanotide)
InjectableCompounded / individualizedBremelanotide is FDA-approved as Vyleesi for premenopausal women with acquired, generalized HSDD. Any compounded version is not FDA-approved.
Oral
Compounded Tadalafil
OralCompounded / individualizedA compounded tadalafil option that may be considered for selected patients. Compounded tadalafil is not FDA-approved and is not the same as a generic FDA-approved product.
Oral
Compounded Sildenafil
OralCompounded / individualizedA compounded sildenafil option that may be considered for selected patients. Compounded sildenafil is not FDA-approved and is not the same as a generic FDA-approved product.
How these options are considered
A clinician reviews symptoms, relevant medical history, and medication use before determining whether any prescription path is appropriate. Product selection and availability vary by patient and state.
Prescription and safety screening required
- Compounded PDE5 products are not FDA-approved and should not be presented as equivalent to FDA-approved generic or brand drugs.
- PDE5 inhibitors are contraindicated with nitrates and require clinician review of cardiovascular history and medication use.
- Bremelanotide has a narrower FDA-approved indication than the category as a whole and should be evaluated case by case.